PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis Therapeutics Market - New analysis from Frost & Sullivan, European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013
Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis Therapeutics Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/07/18 - New analysis from Frost & Sullivan, European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The European endometriosis therapeutics market will experience sustained growth in the coming years.Rising awareness about the condition coupled with the anticipated launch of improved products will be the major driving forces in market expansion.

New analysis from Frost & Sullivan (pharma.frost.com), European Endometriosis Therapeutics Market, finds that this market was valued at $365.0 million in 2006 and estimates this to reach $511.6 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the latest analysis of the European Endometriosis Therapeutics Market, send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore@[.]frost.com with your full name, company name, title, telephone number, email address, city, state and country. We will send you the
information through email upon receipt of the above information.

"With a large untreated population, endometriosis remains a considerably underdeveloped market," says Frost & Sullivan Research Analyst Vaibhav Sarvesh. "However, patient awareness about the condition has been increasing, setting the stage for enhanced market penetration."

The projected introduction of novel products with better side effects together with changing raising awareness will help increase adoption levels of endometriosis therapeutics across Europe.
"GnRH Antagonist and progestins with longer treatment periods will be the most important treatment options that will support market expansion," notes Mr. Sarvesh. "Heightened awareness due to information dissemination campaigns, paralleled by the availability of products with enhanced safety profiles will positively impact market growth."

The current lack of efficient and non-invasive diagnostic procedures as well as the negative side effects of existing therapeutics is restraining the market from growing at its real potential. An aging population and restrictive reimbursement policies are further impeding market growth. "Laparoscopy is considered the gold standard for the diagnosis of endometriosis, but this procedure is invasive and costly," adds Mr. Sarvesh. "No new procedures are expected to be launched in the near future, thereby will continue to hinder market growth."

At the same time, the side effect of current treatment options, particularly the effect of some of the drugs on bone density, will pose a major challenge to market expansion until new treatments are introduced.
Considering the large population of untreated patients, increasing awareness will be the key to market growth. Promoting knowledge about the disease coupled with the launch of drugs with fewer side effects will be critical to sustaining market development. Although antagonists are expected to drive the market in the future, success also awaits any innovative therapeutic approach such as the use of progestin modulators.

European Endometriosis Therapeutics Market is part of the Pharmaceutical & Biotechnology Growth Partnership Service, which also includes research in the following markets: European Urinary Incontinence Therapeutics Market, European Blockbusters coming off patent - Opportunities for Generics, and European Osteoarthritis Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Increasing Awareness and Improved Drug Options Hold Key to Future of European Endometriosis Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
rmtheodore@[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)